ALNYLAM PHARMACEUTICALS INC
Alnylam Pharmaceuticals (ALNY) is a biotechnology company that develops RNA interference (RNAi) therapeutics to silence disease-causing genes. Investors should know it has moved from research-stage to a commercial entity, with multiple approved medicines for rare genetic disorders — including treatments for hereditary ATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria — and a broad pipeline built on its GalNAc delivery platform. The business is growth-oriented: revenues depend on uptake of marketed drugs, pricing and successful launches of late-stage candidates. Key risks include trial outcomes, regulatory decisions, pricing pressures, manufacturing scale-up and competition from other modalities. With a market capitalisation near $62.13 billion, Alnylam may appeal to investors seeking exposure to innovative therapeutics, but it suits those comfortable with biotech volatility. This is general information for educational purposes only and not personalised investment advice; values can fall as well as rise.
Why It's Moving
Needham Boosts ALNY Price Target on Robust 2026 Sales Outlook Signaling Biotech Momentum.
- Needham lifted target to $529 from $520 with Buy rating intact, driven by 2026 product sales forecast of $4.9-5.3B beating consensus by over $400M.
- TTR sales guidance of $4.4-4.7B tops estimates by 7%, highlighting strength in flagship drugs like Amvuttra amid expanding cardiomyopathy indications.
- Analysts flock to Strong Buy consensus, with recent upgrades reflecting optimism over 53% revenue growth and key 2026 launches.
Needham Boosts ALNY Price Target on Robust 2026 Sales Outlook Signaling Biotech Momentum.
- Needham lifted target to $529 from $520 with Buy rating intact, driven by 2026 product sales forecast of $4.9-5.3B beating consensus by over $400M.
- TTR sales guidance of $4.4-4.7B tops estimates by 7%, highlighting strength in flagship drugs like Amvuttra amid expanding cardiomyopathy indications.
- Analysts flock to Strong Buy consensus, with recent upgrades reflecting optimism over 53% revenue growth and key 2026 launches.
When is the next earnings date for ALNYLAM PHARMACEUTICALS INC (ALNY)?
Alnylam Pharmaceuticals (ALNY) is scheduled to report its next earnings on April 30, 2026, before the market opens, with a conference call at 8:30 AM ET. This release will cover the first quarter of 2026, ending March 31, 2026. The prior quarter's results were reported on February 12, 2026, aligning with the company's typical late-month pattern for quarterly disclosures.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Alnylam Pharmaceuticals' stock with a target price of $495.04, indicating growth potential.
Financial Health
Alnylam Pharmaceuticals is generating strong profits and revenue, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring ALNY
Pioneers Of Safer Gene Therapies
Discover a carefully selected group of innovative companies developing alternatives to traditional viral vector gene therapies. These stocks represent biotechs working on potentially safer genetic medicine technologies like siRNA and antisense oligonucleotides, handpicked by professional analysts for their pioneering approaches.
Published: July 21, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
RNAi platform potential
Alnylam’s GalNAc delivery platform enables targeted gene silencing across liver-related diseases, which could drive long-term growth, though clinical and commercial execution matters.
Clinical catalysts ahead
Late-stage trial readouts and new approvals can be material share-price catalysts; remember that trial or regulatory setbacks can also move the stock substantially.
Rare-disease reach
Market opportunity centres on rare, high‑need conditions where few therapies exist, but pricing, access and competition will influence commercial outcomes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
